Introduction
Clinical risk assessment of prostate cancer is imperfect. While adjunctive tools such as genomic classifiers, molecular biomarkers and prostate multiparametric MRI (mpMRI) have shown promise for improving risk categorisation when combined with standard TRUS-guided biopsy [1, 2] , a significant number of patients who undergo radical prostatectomy (RP) will harbour worse disease features (pathological Gleason upgrading or pathological upstaging) than clinically predicted [3] . With current guidelines advocating active surveillance (AS) as the standard for patients with National Comprehensive Cancer Network (NCCN) very-low-and low-risk prostate cancer [4] , the risk of pathological upgrading/upstaging after deferred radical therapy is of increasing concern [5] . However, the clinical and prognostic significance of pathological upgrading/ upstaging from clinical very-low-and low-risk disease remains controversial [6, 7] . In addition, novel molecular biomarkers and genomic classifiers have shown accuracy in predicting adverse pathology and biochemical recurrence (BCR) after RP and help to risk stratify patients who are candidates for AS [8] [9] [10] [11] . Previous work has shown that lowrisk patients have improved rates of BCR amongst those with adverse pathology at RP [12] . However, whether adverse pathology or BCR negatively impacts harder endpoints, such as metastases and survival in clinical low-risk patients' remains unclear.
We therefore investigated the role that preoperative clinical risk plays in estimating the risk of oncological outcomes, including BCR, distant metastases, and cancer-specific survival (CSS), in the context of adverse pathological features, including upstaging and upgrading.
Patients and Methods
After obtaining Institutional Review Board approval, we identified 11 925 patients who underwent primary RP at the Memorial Sloan Kettering Cancer Center (MSKCC) between 1987 and 2015. We also identified 4 868 patients who underwent primary RP at the Cleveland Clinic Foundation (CCF) between 1987 and 2008. Patients were excluded if they were unable to be assigned a D'Amico risk classification due to missing data (n = 462), leaving 16 341 patients in the final cohort.
We aimed to assess the association between preoperative risk and the risk of BCR and distant metastases amongst men subsequently found to have adverse pathology. D'Amico risk classifications were used to identify clinically low-, intermediate-and high-risk prostate cancer. We addressed the problem in both directions, that is, we asked both 'For men with high-risk surgical pathology, is preoperative risk associated with outcome?' and 'For men with low preoperative risk, is high-risk surgical pathology associated with outcome?'.
For the first set of analyses, we examined the role of preoperative risk amongst four cohorts of men who were identified based on the presence of four adverse pathological features: men with extracapsular extension (ECE), seminal vesicle invasion (SVI), lymph node involvement (LNI), and pathological Gleason score ≥7. In each cohort, we calculated Kaplan-Meier estimates and used log-rank tests to test for differences in BCR-free survival, metastasis-free survival and CSS between men with adverse pathological features who had clinical low-risk disease and men who did not have clinical low-risk disease. To assess whether the association between preoperative risk and oncological outcomes for men with adverse pathology persist when controlling for other pathological features, we created a multivariable Cox proportional hazards model that was adjusted for preoperative PSA level, pathological Gleason score (≤6, 7 or ≥8), and the presence of ECE, SVI and LNI (N0, N1, or Nx), and applied this model separately to each cohort. To investigate whether clinical risk affected the risk of BCR, distant metastasis, or CSS differently between the two cohorts, the analyses were repeated separately in each cohort, and heterogeneity chi-squared tests, using Cochran's Q, were performed. (1.8, 8 .0) years. There were 5 596 and 2 124 men followed for 5 and 10 years without BCR, respectively. Meanwhile, 7 028 and 2 900 men were followed for 5 and 10 years without distant metastasis, respectively. A total of 2 121 men were followed for 10 years without BCR, distant metastasis, or death from prostate cancer.
Oncological outcomes were assessed in four cohorts of men. The ECE cohort included 5 557 men, of whom 1 016 (18%) had low-risk disease. The SVI cohort included 1 406 men, with 70 of those men having low-risk disease (5%). The LNI cohort included 970 men, with 23 men having low-risk disease (2.4%). In all, 2 163 (45%) of the CCF patients did not undergo lymphadenectomy, which was mainly due to the low nomogram-predicted risk of LNI based on clinical features and non-suspicious nodes at the time of RP. The largest cohort included 10 836 men with pathological Gleason scores ≥7, of whom 2 955 had low-risk disease (27%) preoperatively.
The results of our first set of analyses are shown in Table 2 . Amongst men with adverse features on surgical pathology, preoperative low-risk status was associated with an~50% and 70% reduction in the risk of prostate cancer death and metastasis, respectively. The results for LNI differ slightly, but these analyses are based on very small numbers of patients As patients from two cohorts were included, we also investigated whether there was heterogeneity between institutions in the effect of clinical low-risk disease on oncological outcomes. We found significant heterogeneity between sites for the outcome of BCR-free survival when comparing patients amongst patients with ECE or LNI, and for the outcomes of BCR-free and metastasis-free survival amongst patients with pathological Gleason score ≥7. For cases where significant heterogeneity in effect size was found, having clinical low-risk was associated with a reduction in risk of BCR or distant metastasis at both institutions, with one exception. The multivariable model for BCR-free survival amongst the CCF patients with LNI showed a non-significant increase in risk of BCR for low-risk patients (hazard ratio [HR] 1.64, 95% CI 0.58, 4.66, P = 0.4). However, there were only five patients from the CCF cohort who were clinically low-risk and had LNI.
As a sensitivity analysis, we removed 4 428 MSKCC patients treated between 2009 and 2015 to restrict the cohort to the same years for both sites. No appreciable changes in the results were seen when excluding these patients.
Our second set of analyses examined whether pathological upstaging or upgrading influenced survival outcomes in men with low-risk disease. Baseline characteristics for this group are described in Table 3 . Of the 2 297 CCF D'Amico low-risk patients identified, 1 305 (57%) had any pathological upgrading or upstaging, whilst 992 (43%) did not have any pathological upgrading or upstaging (Table 4) . When isolating pT3a upstaging only, regardless of pathological Gleason score, 402 (18%) patients had such reclassification, Table 4 . Of all types of pathological reclassification, only upgrading to Gleason score ≥8 and upstaging to SVI or LNI were associated with worse CSS. However, reclassification based on Gleason score ≥8 or SVI or LNI was seen in only 62 (3%) patients. As there were only eight deaths from prostate cancer in the CCF cohort, a multivariable analysis was not performed.
Discussion
AS in patients with low-risk prostate cancer is underutilised [13] , and may be attributed, in part, to the perceived risk of upgrading or upstaging at RP. Our present analysis of patients from the MSKCC and CCF who underwent RP between 1987 and 2015 suggests that in patients who are candidates for AS based on clinical features, pathological upgrading or upstaging from clinical low-risk prostate cancer has limited long-term effects on BCR, metastasis-free survival and CSS rates amongst patients with adverse pathological features. Intuitively, we believe that when matched for adverse pathological findings, clinically low-risk patients will have superior outcomes when compared to clinically Our present results beg the question: why do patients with adverse pathological features have differing outcomes based on clinical features? We believe that the overall clinical picture of low-risk patients should be considered, regardless of final pathology. Clinically low-risk patients present not only with Gleason scores ≤6, but also with low serum PSA levels (<10 ng/mL) and clinically undetectable or minimally detectable disease volume (T1c or T2a). While we did not perform tumour volumetric analysis on our present cohorts, we suspect that we would observe smaller tumour volumes in clinically low-risk patients. We also believe that the biology of clinical low-risk prostate cancer that exhibit adverse pathological features is different from those that present clinically with adverse features, even if the final pathological specimens are categorised similarly. There is strong evidence to suggest that there is considerable biological heterogeneity amongst clinical risk groups and we believe that these prior findings help to explain our present results [10] .
We believe that our present results confirm the utility of standard TRUS-guided biopsy alone as a risk-assessment tool for low-risk patients who are candidates for AS. While prostate mpMRI, molecular-based biomarkers and genomic classifiers aim to identify patients who potentially harbour more adverse pathological features than clinically detected using traditional techniques, we question the value of identifying those that potentially harbour ECE or Gleason score 3+4 disease, as their BCR, metastasis and survival rates do not seem to be adversely affected when compared to those without such pathological features. Furthermore, we found that the absolute rate of the most severe forms of pathological reclassification was very low. Whether adjunctive tools are both sufficiently accurate and cost-effective for identifying the most severe adverse pathological features in a clinically lowrisk population remains to be seen.
Additionally, we found that amongst low-risk patients with adverse pathological features and who developed BCR, the risk of subsequent prostate cancer-related metastases or death was about half the risk of BCR, suggesting that BCR does not necessarily lead to morbidity from metastases or death. These findings are consistent with previous reports [12] .
Our present study results reflect those of previous analyses. In a recent study, similar BCR rates were seen amongst AS candidates who were pathologically upgraded from Gleason 3+3 to 3+4 [14] . Meanwhile, Muralidhar et al. [15] reported that patients with occult T3 disease exhibit better CSS than patients with clinical T3 disease. However, we believe our present study is the first to analyse BCR, metastasis-free and survival rates from the viewpoint of both adverse pathological features, stratified by D'Amico clinical risk and from the viewpoint of pathological upstaging from clinical D'Amico low-risk disease. Our analyses from both vantage points reached similar conclusions. In addition, we believe our present analysis of 2 297 CCF patients with clinical low-risk disease and who were pathologically upgraded and/or upstaged at RP is the first to study various definitions of pathological reclassification with such granularity.
Our present study has several limitations. Firstly, the retrospective nature of our present study lends itself to inherent biases. For example, our cohorts likely carry a selection bias, as many patients diagnosed with clinically very-low-or low-risk disease at our respective institutions pursue AS rather than curative treatments such as surgery or radiation. However, AS for low-risk disease as the accepted standard is relatively novel and was not widely employed at our respective institutions until the latter part of the study period, thus limiting the selection bias in our study population. Furthermore, previous reports have found no difference in pathological outcomes between low-risk AS patients who underwent deferred RP vs clinically similar patients who underwent immediate RP [16] . Secondly, prostate mpMRI and other adjunctive classifying tools were not routinely performed on our present patient population. However, in current contemporary practice, only 6.5% of biopsy-na€ ıve men undergo prostate MRI before biopsy [17] . Our present study is therefore germane to the current state of urological practice. Moreover, although a recent randomised trial concluded that MRI with MRI-fusion biopsy identifies more significant (Gleason score ≥3+4) prostate cancer than standard TRUS-guided biopsy in biopsy-na€ ıve men [18] , only 3% of patients in the CCF cohort had significantly adverse pathological upgrading/upstaging. This calls into question the need for such adjunctive tools in a clinically low-risk population. Thirdly, while both cohorts were similar in most respects, heterogeneity analysis revealed that certain clinical characteristics of the MSKCC and CCF cohorts had different and statistically significant effects on BCR, metastases-free, and CSS. Finally, our study period was long Despite these limitations, we believe our present study contributes significant understanding regarding the long-term outcomes of patients with clinically low-risk prostate cancer regardless of adverse reclassification at RP. We believe that patients who exhibit either upgrading or upstaging at RP should be counselled that their long-term risk of adverse outcome is not necessarily worse than patients without pathological reclassification. In particular, predicted risk of upstaging or upgrading should not be used to recommend immediate treatment in patients with low-risk prostate cancer who are eligible for AS.
Conclusion
Clinically low-risk patients with adverse pathological findings at RP have substantially lower rates of important oncological outcomes compared to those with higher clinical risk and not substantially different than low-risk patients without upgrading or upstaging. These results call into question the risk of adverse pathological reclassification as an endpoint to counsel patients about the merits and risks of AS.
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